SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report

SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report

Abstract Background Hyperglycemia is the most common side-effect of phosphatidylinositol 3-kinase (PI3K) inhibitors that are approved for the treatment of some advanced or metastatic breast cancers. This side-effect is likely due to the central role of PI3K in insulin signalling. Here we report the...

Full description

Bibliographic Details
Main Authors: Nicolas Sahakian, Lauranne Cattieuw, Clotilde Ramillon-Cury, Audrey Bégu-Le Corroller, Pascale Silvestre-Aillaud, Sophie Béliard, René Valéro
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Clinical Diabetes and Endocrinology
Subjects:
Cancer treatment
Case report
Diabetes
Hyperglycemia
Insulin resistance
Metabolic side effects
Online Access:https://doi.org/10.1186/s40842-021-00125-8

Similar Items

Similar Items